Immune Design to Report Third Quarter 2016 Financial Results & Present at Upcoming Investor Conference

SEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 02, 2016 -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on cancer, today announced that it will report third quarter 2016 financial results after the close of U.S. financial markets on Wednesday, Nov. 9, 2016. Immune Design management will host a webcast and conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on Nov. 9, 2016 to discuss the financial results and provide a corporate update.

The live call may be accessed by dialing 844-266-9538 for domestic callers and 216-562-0391 for international callers. A live webcast of the call will be available online from the investor relations section of the company website at http://ir.immunedesign.com/events.cfm and will be archived there for 90 days. A telephone replay of the call will be available for five days by dialing 855-859-2056 for domestic callers or 404-537-3406 for international callers and entering the conference code: 10923483.

In addition, Immune Design announced that Carlos Paya, M.D., Ph.D., President and Chief Executive Officer, will present at the Jefferies 2016 London Healthcare Conference on Wednesday, November 16, 2016 at 8:40 a.m. GMT, 3:40 a.m. Eastern time, in London.

A live webcast of the presentation will be available online from the investor relations page of the company's corporate website at http://ir.immunedesign.com/events.cfm. After the live webcast, an archive of the presentation will be available on the company website.

About Immune Design

Immune Design is a clinical-stage immunotherapy company employing next-generation in vivo approaches to enable the body's immune system to fight disease. The company's technologies are engineered to activate the immune system's natural ability to generate and/or expand antigen-specific cytotoxic T cells, while also enhancing other immune effectors, to fight cancer and other chronic diseases.  CMB305 and G100, the two-pronged focus of Immune Design's ongoing immuno-oncology clinical programs, are the product of its two synergistic discovery platforms, ZVex^TM and GLAAS^TM. Immune Design has offices in Seattle and South San Francisco. For more information, visit www.immunedesign.com.

Media Contact
Julie Rathbun
Rathbun Communications
[email protected]                   
206-769-9219

Investor Contact
Shari Annes
Annes Associates
[email protected]
650-888-0902